Andersen-Tawil syndrome primary prevention: Difference between revisions
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Andersen-Tawil syndrome}} | {{Andersen-Tawil syndrome}} | ||
{{CMG}}; {{AE}} {{ | {{CMG}}; {{AE}} {{VKG}} | ||
== Overview == | == Overview == | ||
Effective measures for the primary prevention of Andersen-Tawil syndrome (ATS) include | Effective measures for the primary prevention of [[Andersen-Tawil syndrome]] ([[Andersen-Tawil syndrome|ATS]]) include [[lifestyle]] modifications, [[carbonic anhydrase inhibitors]] using, [[potassium]] supplements and [[cardioverter-defibrillator]]. | ||
== Primary Prevention == | == Primary Prevention == | ||
Effective measures for the primary prevention of Andersen-Tawil syndrome (ATS) include: | Effective measures for the primary prevention of [[Andersen-Tawil syndrome]] ([[Andersen-Tawil syndrome|ATS]]) include: | ||
* Lifestyle modification if applicable | *[[Lifestyle]] modification if applicable | ||
*Dietary modification if applicable | *[[Dietary]] modification if applicable | ||
* Carbonic anhydrase inhibitors use like acetazolamide | *[[Carbonic anhydrase inhibitors]] use like [[acetazolamide]] | ||
**Preferred regimen (1): Acetazolamide adults 125-1,000 mg daily, children 5-10 mg/kg/day | **Preferred regimen (1): [[Acetazolamide]] adults 125-1,000 mg daily, children 5-10 mg/kg/day | ||
* Potassium supplements | *[[Potassium]] supplements | ||
**Slow release potassium supplements may be helps with hypokalemic periodic paralysis | **Slow release potassium supplements may be helps with [[hypokalemic periodic paralysis]] | ||
*Implantable cardioverter-defibrillator | *[[Implantable cardioverter defibrillator|Implantable cardioverter-defibrillator]] | ||
**Implantable cardioverter- | **[[Implantable cardioverter defibrillator|Implantable cardioverter-defibrillato]]<nowiki/>r is an idle choice in patients with [[tachycardia]]-induced [[syncope]] | ||
==References== | ==References== | ||
Latest revision as of 18:47, 17 February 2020
|
Andersen-Tawil syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Andersen-Tawil syndrome primary prevention On the Web |
|
American Roentgen Ray Society Images of Andersen-Tawil syndrome primary prevention |
|
Risk calculators and risk factors for Andersen-Tawil syndrome primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vamsikrishna Gunnam M.B.B.S [2]
Overview
Effective measures for the primary prevention of Andersen-Tawil syndrome (ATS) include lifestyle modifications, carbonic anhydrase inhibitors using, potassium supplements and cardioverter-defibrillator.
Primary Prevention
Effective measures for the primary prevention of Andersen-Tawil syndrome (ATS) include:
- Lifestyle modification if applicable
- Dietary modification if applicable
- Carbonic anhydrase inhibitors use like acetazolamide
- Preferred regimen (1): Acetazolamide adults 125-1,000 mg daily, children 5-10 mg/kg/day
- Potassium supplements
- Slow release potassium supplements may be helps with hypokalemic periodic paralysis
- Implantable cardioverter-defibrillator
- Implantable cardioverter-defibrillator is an idle choice in patients with tachycardia-induced syncope